



Irinotecan (Camptosar®)

Revision: 2

Policy Number: M-0020

Last Update: 6/4/2014

Payment will not be made for any use of these drugs outside of the criteria without prior authorization. The member may not be billed unless the member explicitly agrees in writing to be responsible for the charges in accordance with the contract/provider manual. Prior authorization will only be given if the provider demonstrates the intended use meets Medicare coverage guidelines.

When appropriate compendia references the use of one of the chemotherapeutic agents listed in this Article as part of a 'combination therapy', the drug is only approved for use in such 'combinations', and the documentation should reflect, and be specific about, the use of the additional 'combination therapy' drugs.

Coverage Guidelines:

FDA:

- Metastatic colorectal cancer, First-line therapy, in combination with 5-fluorouracil and leucovorin
- Metastatic colorectal cancer, In patients whose disease has recurred/progressed after initial 5-fluorouracil-based therapy

Off Label:

- Acute lymphoid leukemia
- Acute myeloid leukemia
- Carcinoma of cervix
- Carcinoma of esophagus
- Colorectal cancer
- Extensive stage small cell lung cancer, First-line treatment, in combination with carboplatin
- Extensive stage small cell lung cancer, First-line treatment, in combination with cisplatin
- Gastric cancer
- Malignant glioma of brain, Recurrent or progressive disease
- Metastatic breast cancer, Refractory



- Non-Hodgkin's lymphoma
- Non-small cell lung cancer
- Ovarian cancer, Platinum-refractory or platinum-resistant

Coding Information:

HCPCS Code(s)

J9206	INJECTION, IRINOTECAN, 20 MG
-------	------------------------------

ICD-9 Code(s)

150.0-150.9	MALIGNANT NEOPLASM OF CERVICAL ESOPHAGUS - MALIGNANT NEOPLASM OF ESOPHAGUS UNSPECIFIED SITE
151.0-151.9	MALIGNANT NEOPLASM OF CARDIA - MALIGNANT NEOPLASM OF STOMACH UNSPECIFIED SITE
153.0-153.9	MALIGNANT NEOPLASM OF HEPATIC FLEXURE - MALIGNANT NEOPLASM OF COLON UNSPECIFIED SITE
154.0-154.8	MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION - MALIGNANT NEOPLASM OF OTHER SITES OF RECTUM RECTOSIGMOID JUNCTION AND ANUS
157.0-157.9	MALIGNANT NEOPLASM OF HEAD OF PANCREAS - MALIGNANT NEOPLASM OF PANCREAS PART UNSPECIFIED
162.0-162.9	MALIGNANT NEOPLASM OF TRACHEA - MALIGNANT NEOPLASM OF BRONCHUS AND LUNG UNSPECIFIED
183.0	MALIGNANT NEOPLASM OF OVARY
191.0-191.9	MALIGNANT NEOPLASM OF CEREBRUM EXCEPT LOBES AND VENTRICLES - MALIGNANT NEOPLASM OF BRAIN UNSPECIFIED SITE

Background:

Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It works by stopping the growth of cancer cells.



Black Box Warning:

WARNINGS

CAMPTOSAR Injection should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available. CAMPTOSAR can induce both early and late forms of diarrhea that appear to be mediated by different mechanisms. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion of CAMPTOSAR) may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Early diarrhea and other cholinergic symptoms may be prevented or ameliorated by atropine. Late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Late diarrhea should be treated promptly with loperamide. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Administration of CAMPTOSAR should be interrupted and subsequent doses reduced if severe diarrhea occurs. Severe myelosuppression may occur.

Definitions:

HCPCS Code—Healthcare Common Procedure Coding System - A system of letter and number codes assigned to procedures, medications, supplies and equipment used for pricing and billing.

ICD-9 Code—International Classification of Disease, 9th edition. A standardized classification of disease, injuries, and causes of death, by etiology and anatomic localization and codified into a 6-digit number, which allows clinicians, statisticians, politicians, health planners and others to speak a common language, both US and internationally.

References:

1. Camptosar [package insert]. New York, NY: Pfizer Injectables; August 2010. Available at: <http://labeling.pfizer.com/ShowLabeling.aspx?id=533>.. June 7, 2012.



2. The NCCN Drugs & Biologics Compendium™ © 2010 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed May 23, 2012.
3. Local Coverage Article for Drugs and Biologicals – Chemotherapeutic Agents (A48896) (R4). Available at: http://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=48896&ver=89&ContrId=213&ContrVer=1&CtrctrSelected=213*1&Date=01%2f01%2f2013&DocID=A48896&bc=hAAAAAgAEAAAAA%3d%3d&. Accessed June 4, 2014.
4. Micromedex® 2.0 Camptosar. Available at: http://www.thomsonhc.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/DE0881/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/080E28/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.DisplayDrugpointDocument?docId=923686&contentSetId=100&title=Irinotecan+Hydrochloride&servicesTitle=Irinotecan+Hydrochloride&topicId=dosingAndIndicationsSection&subtopicId=nonfdaSection.. Accessed 6-7-12

Document History:

Date Written: 6/7/12

Effective Date: 4/1/13

Revision 1: 3/19/2013

Revision 2: 6/4/2014

Internal Review: 6/11/2014

External Review: 6/17/2014

For the Archived Policy, please go

to <http://www.vivaprovider.com/Resources/CoveragePolicies.aspx> and click on the Archived Policies Link.